Assessing the efficacy of Elixirium thymi compositum in the treatment of acute bronchitis in pediatric patients (EXOTIC): A double-blind, randomized, placebo-controlled, phase 4 study

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520845-61-00

Acronym

EXOTIC

Enrollment

Registered

2025-05-07

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute bronchitis

Brief summary

Efficacy of the investigational product based on the Bronchitis Severity Score

Detailed description

Safety and tolerability by the reported adverse events

Interventions

DRUGElixirium thymi compositum (fono viii.) placebo

DRUGElixirium thymi compositum FoNo VIII. Naturland belsőleges oldat

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Efficacy of the investigational product based on the Bronchitis Severity Score	—

Secondary

Measure	Time frame
Safety and tolerability by the reported adverse events	—

Countries

Hungary

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026